EUCTR2004-004806-25-DE进行中（未招募）不适用
Evaluation of the complete remission rates in patients with symptomatic non-erosive reflux disease (NERD) or erosive gastroesophageal reflux disease (GERD) treated with pantoprazole 40 mg o.d. over 4 or 8 or 12 weeks - Complete Remission
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 1,200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •-Written informed consent by the patient for study participation, prior to protocol specific procedures
- •- Outpatients of at least 18 years of age
- •- Reflux disease related symptoms for at least 12 weeks, which need not be consecutive, in the previous 12 months or endoscopically confirmed reflux esophagitis grade A to D according to LA-classification
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Signs, indicating other gastrointestinal diseases:
- •- Zollinger-Ellison syndrome or other gastric hypersecretory condition
- •- Previous acid-lowering surgery or other surgery of the esophagus and/or upper gastrointestinal tract (exception: polypectomy and cholecystectomy)
- •- On initial endoscopy, presence of obstructive esophageal strictures, Schatzki’s ring, esophageal diverticula, esophageal varices, achalasia or Barrett’s esophagus with known high-grade dysplasia or longer than 3 cm
- •- Acute peptic ulcer and/or ulcer complications
- •- Pyloric stenosis
- •- Inflammatory bowel diseases
- •Other concomitant diseases:
- •- Severe or unstable cardiovascular (e.g., severe angina pectoris, postmyocardial infarction and ventricular extrasystoles), pulmonary, or endocrine disease; clinically significant renal or hepatic disease or dysfunction; hematologic disorder; any other clinically significant medical condition that could increase the risk to the study participant
- •- Malignant disease of any kind during the previous 5 years except for successfully treated skin (basal or squamous cell) cancer
- •- Tendency to react allergically to drugs, especially with known hypersensitivity to one of the compounds of the study medication
- •- Alcohol, drug or medication abuse within the past year
- •- Abnormal laboratory parameters and vital signs considered as clinically relevant by the investigator
- •- Severe psychiatric or neurologic disorders
- •Special restrictions for female patients:
- •- Pregnant or nursing female patients
- •- Female patients of childbearing potential, not using and not willing to continue using a medically reliable method of contraception for the entire study duration, such as oral, injectable, or implantable contraceptives, or intrauterine contraceptive devices, unless they are surgically sterilized/hysterectomized or who are not using any other method considered sufficiently reliable by the investigator in individual cases
- •Previous medication:
- •- PPIs during the last 14 days before the start of the study
- •- H2-receptor antagonists and prokinetics during the last 7 days before the start of the study
- •- Any medication for the purpose of the eradication of H. pylori during the last 28 days before the start of the study
- •- Systemic glucocorticoids or non-steroidal anti-inflammatory drugs (NSAIDs) including COX-2-inhibitors (> 5 days on demand but not more than 3 consecutive days) during the last 28 days before the start of the study; except regular intake of acetylsalicylic acid in dosages up to 150 mg/d
- •Concomitant medication:
- •- PPIs (except study medication), H2-receptor antagonists, prokinetics, sucralfate, misoprostol and bismuth preparations
- •- Systemic glucocorticoids or non-steroidal anti-inflammatory drugs (NSAIDs) including COX-2-inhibitors (> 5 days on demand but not more than 3 consecutive days) except regular intake of acetylsalicylic acid in dosages up to 150 mg/d
- •- Ketoconazole or other drugs with pH dependent absorption
- •- PPIs in combination with antibiotics for the purpose of the eradication of H. pylori
- •- Patients who are expected to be non-compliant and/or not cooperative
- •- Participation in a clinical study within the last 30 days prior to the start of the study
- •- Patients who have participated already in this study
- •- Patients who are employees at the investigational site, relative or spouse of the investigator
- •- Any donation of germ cells, blood, organs, or bone marrow during the course of the study
- •- Patients who are not contractually
研究者
相似试验
进行中（未招募）
1 期
Evaluation of the complete remission rates in patients with symptomatic non-erosive reflux disease (NERD) or erosive gastroesophageal reflux disease (GERD) treated with pantoprazole 40 mg o.d. over 4 or 8 or 12 weeks - Complete RemissionGastroesophageal reflux diseaseMedDRA version: 5.0Level: lltClassification code 10038263EUCTR2004-004806-25-HUALTANA Pharma AG
进行中（未招募）
不适用
Evaluation of the complete remission rates in patients with symptomatic non-erosive reflux disease (NERD) or erosive gastroesophageal reflux disease (GERD) treated with pantoprazole 40 mg o.d. over 4 or 8 or 12 weeks - Complete RemissioGastroesophageal reflux diseaseMedDRA version: 5.0Level: lltClassification code 10038263EUCTR2004-004806-25-ATALTANA Pharma AG1,200
招募中
3 期
The therapeutic effect of inhaled budesonide in patients with unexplained chronic cough.IRCT2013031212419N2The budget will be funded by researchers.68
进行中（未招募）
不适用
Evaluation of the rate of pathological complete response rate (pCR) for neoadjuvant chemoradiotherapy (CR-RT) and for chemotherapy (CT) alone in locally advanced non small cell lung cancer (LA-NSCLC): a randomised phase II trialEUCTR2005-005139-84-ATPIERRE FABRE MEDICAMENT200
进行中（未招募）
不适用
Evaluation of the rate of pathological complete response rate (pCR) for neoadjuvant chemoradiotherapy (CT-RT) and for chemotherapy (CT) alone in locally advanced non small cell lung cancer (LA-NSCLC): a randomised phase II trialocally advanced non small cell lung cancerEUCTR2005-005139-84-CZPIERRE FABRE MEDICAMENT200